GFH276
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for GFH276, covering 2025-09-30 to 2025-09-30. Get the full timeline:
Most recent: Clinical Trial Update: A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors [Phase 1, Phase 2]